Business Wire

Imperva Application Security Integrates API Detection and Response, Setting A New Standard in API Security

24.6.2025 09:00:00 CEST | Business Wire | Press Release

Share

Thales today announced new detection and response capabilities in the Imperva Application Security platform to protect against business logic attacks, such as Broken Object Level Authorization (BOLA) – the leading threat in the OWASP API Security Top 10. By integrating real-time detection with automated mitigation of risky APIs, BOLA attacks, unauthenticated APIs, and deprecated APIs, Imperva Application Security platform delivers comprehensive protection against unauthorized data exposure and other complex business logic vulnerabilities across cloud and on-premises environments.

APIs have become the backbone of modern applications, enabling businesses to seamlessly connect services, optimize operations, and deliver personalized experiences at scale. According to Imperva Threat Research, APIs accounted for 71% of all web traffic. More recently, the team observed a sharp rise in API-directed attacks, with 44% of advanced bot traffic targeting APIs, compared to just 10% targeting web applications. This shift underscores how attackers are increasingly exploiting API endpoints that manage sensitive and high-value data.

Why BOLA is a Critical Business Risk

BOLA occurs when APIs fail to properly verify whether users are authorized to access specific data objects. This allows attackers to manipulate requests and gain unauthorized access to sensitive information. As the leading OWASP Top 10 API threat, BOLA exposes businesses to significant risks, including data breaches, compliance failures, and loss of customer trust.

“API security is no longer optional – it’s fundamental to maintaining business continuity and trust,” said Tim Chang, Global Vice President and General Manager of Application Securityat Thales. “Imperva Application Security bridges the gap by delivering a fully unified platform that identifies business logic threats and actively blocks malicious sessions, setting a new benchmark for API protection.”

Empowering Enterprises with a Unified, Flexible, and Privacy-First Solution

Imperva Application Security integrates advanced threat detection engines with automated inline responses and flexible deployment options, enabling security teams to detect and respond to API attacks like BOLA without slowing development or disrupting the user experience. For customers who want to protect their API infrastructure, Imperva Application Security delivers the following benefits:

  • Unified Platform Architecture: Manage API discovery, risk assessment, detection, and mitigation in a single console, eliminating tool sprawl and operational friction across cloud and on-premises environments.
  • Real-Time BOLA Detection: Hybrid behavioral and rule-based engines analyze API request patterns, scoring anomalies, and flagging endpoints for immediate action.
  • Automated Response and Remediation: Integration with Imperva Cloud WAF and WAF Gateway enables a variety of response actions, including inline mitigation actions such as automatically blocking malicious API traffic in real-time. Integration with security automation tools ensures rapid incident orchestration.

Advancing the Imperva Security Anywhere Vision

The integration of API detection and response into Imperva Application Security is foundational to the Imperva Security Anywhere vision, which provides scalable, end-to-end protection for applications and APIs across any environment. This unified solution provides enterprises with a comprehensive view of automated threats targeting APIs and the necessary tools to protect those APIs.

Detection and response to deprecated APIs, unauthenticated APIs, and BOLA attacks are now available as part of Imperva Application Security.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies for the Defence, Aerospace, and Cyber & Digital sectors. Its portfolio of innovative products and services addresses several major challenges: sovereignty, security, sustainability and inclusion.

The Group invests more than €4 billion per year in Research & Development in key areas, particularly for critical environments, such as Artificial Intelligence, cybersecurity, quantum and cloud technologies.

Thales has more than 83,000 employees in 68 countries. In 2024, the Group generated sales of €20.6 billion.

PLEASE VISIT

Thales Group

Cloud Protection & Licensing Solutions | Thales Group

Cybersecurity Solutions | Thales Group

View source version on businesswire.com: https://www.businesswire.com/news/home/20250624052385/en/

Contacts

Thales, Media Relations
Security & Cybersecurity
Marion Bonnet
+33 (0)6 60 38 48 92
marion.bonnet@thalesgroup.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye